{"nctId":"NCT05842967","briefTitle":"A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease","startDateStruct":{"date":"2023-05-11","type":"ACTUAL"},"conditions":["RESPIRATORY SYNCYTIAL VIRUS (RSV)"],"count":885,"armGroups":[{"label":"Substudy A - RSVpreF","type":"EXPERIMENTAL","interventionNames":["Biological: RSVpreF"]},{"label":"Substudy A - Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Substudy B - RSVpreF","type":"EXPERIMENTAL","interventionNames":["Biological: RSVpreF"]}],"interventions":[{"name":"RSVpreF","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Substudy A Inclusion Criteria:\n\n1. Capable of giving signed informed consent as described per protocol.\n2. Participants ≥18 to \\<60 years of age at study enrollment.\n3. Life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment.\n4. Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.\n5. Participants who are considered at high risk of RSV disease by virtue of the following:\n\n   * Adults with chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).\n\nChronic medical conditions for this substudy are defined as:\n\n\\- Duration greater than 6 months.\n\n* Stable disease not requiring a significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention.\n* Requires regular medical follow-up or ongoing medication or hospitalization in the previous year.\n\n  • Additional groups at high risk include:\n* Residents of nursing homes and other long-term care facilities.\n\nSubstudy A Exclusion Criteria:\n\n1. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.\n3. Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.\n4. Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.\n5. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n6. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n\n   Note: Specific criteria for participants with known stable infection with HIV can be found in protocol.\n7. Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids\\*, eg, for cancer or an autoimmune disease, or radiotherapy, from 60 days before study intervention administration or planned receipt throughout the study.\n\n   \\*Applies to systemic corticosteroids administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Systemic corticosteroids administered at a dose of \\<20 mg/day of prednisone or equivalent are permitted. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.\n8. Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.\n\n   Note: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted, provided they do not meet exclusion criterion 7.\n9. Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.\n10. Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.\n11. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.\n\nSubstudy B Inclusion Criteria\n\n1. Capable of giving signed informed consent as described per protocol.\n2. Participants ≥18 years of age at study enrollment.\n3. Life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment.\n4. Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.\n5. Participants who are immunocompromised by virtue of the following:\n\n   •Having known advanced NSCLC with at least 1 of the following:\n   * Has received initial or maintenance chemotherapy at least 2 weeks (14 days) before enrollment (or is treatment-naïve), and is not expected to receive chemotherapy within at least 2 weeks (14 days) after dose administration of initial vaccination or second vaccination; and/or\n   * Is receiving checkpoint inhibitor treatment (PD-1/PD-L1 inhibitor, CTLA-4 inhibitor) and has undergone at least 1 treatment cycle prior to enrollment; or\n   * Is receiving targeted drug therapy (EGFR, ALK, ROS1, BRAF, RET, MET, NTRK inhibitors) and has undergone at least 1 treatment cycle prior to enrollment.\n\n   OR - Is currently undergoing maintenance hemodialysis treatment secondary to end-stage renal disease . OR - Is on active immunomodulator therapy (eg, TNFα inhibitor, tofacitinib, or MTX) for an autoimmune inflammatory disorder (eg, inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, or inflammatory bowel disease, such as ulcerative colitis or Crohn's disease) at a stable\\*dose.\n\n   \\*Stable dose is defined as receiving the same dose for at least 3 months (84 days) with no changes in the 28 days prior to enrollment. See protocol for details on stable dose for MTX.\n\n   OR - Is receiving an SOT (kidney, liver, lung, or heart) at least 3 months (84 days) prior to enrollment (Visit 201) and with no acute rejection episodes within 2 months (60 days) prior to enrollment (Visit 201).\n\n   Substudy B Exclusion Criteria:\n\n1.Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n\n2.History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.\n\n3.Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions within 3 months (84 days) prior to study enrollment.\n\n4.Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.\n\n5.Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n\nNote: Specific criteria for participants with known stable infection with HIV can be found in protocol.\n\n6.Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration.\n\n7.Receipt of blood/plasma products or immunoglobulin (IVIG, SCIG) within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.\n\nNote: Please see the inclusion criteria in the protocol regarding criteria for targeted immunoglobulin therapies for underlying medical conditions.\n\nNote: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted.\n\n8.Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.\n\n9.Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.\n\n10.Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \\>2.5 cm to 5.0 cm; moderate: \\>5.0 cm to 10.0 cm; severe: \\>10 cm.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination","description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"PRIMARY","title":"SSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years","description":"In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \\>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41097","spread":null},{"groupId":"OG001","value":"26225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37416","spread":null},{"groupId":"OG001","value":"24680","spread":null}]}]}]},{"type":"PRIMARY","title":"SSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years","description":"Seroresponse was defined as achieving a \\>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \\>=4\\* LLOQ was considered a seroresponse.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"88.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","spread":null},{"groupId":"OG001","value":"85.0","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \\> 2.0 cm to 5.0 cm; moderate: \\> 5.0 cm to 10.0 cm and severe: \\> 10 cm.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2","description":"Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \\>2.0 cm to 5.0 cm; moderate: \\>5.0 cm to 10.0 cm and severe: \\>10 cm.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","paramType":"NUMBER","dispersionType":"96% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"22.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"15.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"13.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2","description":"Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \\>=38.0 degrees Celsius (deg C) and categorized as mild: \\>=38.0 to 38.4 deg C, moderate: \\>38.4 to 38.9 deg C and severe: \\>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \\>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"12.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2","description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"22.4","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study","description":"A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: Percentage of Participants With SAEs Throughout the Study","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: GMT of NT for RSV A and RSV B Before Vaccination 1","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2943","spread":null},{"groupId":"OG001","value":"3289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2584","spread":null},{"groupId":"OG001","value":"2992","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26173","spread":null},{"groupId":"OG001","value":"26075","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24701","spread":null},{"groupId":"OG001","value":"25384","spread":null}]}]}]},{"type":"PRIMARY","title":"SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2","description":"GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21910","spread":null},{"groupId":"OG001","value":"25159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20936","spread":null},{"groupId":"OG001","value":"22774","spread":null}]}]}]},{"type":"SECONDARY","title":"SSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"SSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]}]},{"type":"SECONDARY","title":"SSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination","description":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2388","spread":null},{"groupId":"OG001","value":"2797","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41595","spread":null},{"groupId":"OG001","value":"2660","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2075","spread":null},{"groupId":"OG001","value":"2230","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38450","spread":null},{"groupId":"OG001","value":"2135","spread":null}]}]}]},{"type":"SECONDARY","title":"SSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination","description":"GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":453},"commonTop":["Fatigue (FATIGUE)","Injection site pain (PAIN AT INJECTION SITE)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Diarrhoea (DIARRHEA)"]}}}